Positive News Sentiment NASDAQ:PBYI Puma Biotechnology - PBYI Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $4.32 -0.10 (-2.26%) (As of 01/27/2023 03:35 PM ET) Add Compare Share Share Today's Range$4.25▼$4.5150-Day Range$3.75▼$5.0852-Week Range$1.60▼$5.16Volume183,466 shsAverage Volume334,193 shsMarket Capitalization$197.16 millionP/E Ratio19.64Dividend YieldN/APrice Target$8.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Puma Biotechnology MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside85.2% Upside$8.00 Price TargetShort InterestHealthy2.45% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.66Based on 2 Articles This WeekInsider TradingSelling Shares$176,342 Sold Last QuarterProj. Earnings Growth-57.89%From $0.19 to $0.08 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.59 out of 5 starsMedical Sector110th out of 1,055 stocksPharmaceutical Preparations Industry41st out of 519 stocks 3.5 Analyst's Opinion Consensus RatingPuma Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Puma Biotechnology has a forecasted upside of 85.2% from its current price of $4.32.Amount of Analyst CoveragePuma Biotechnology has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.45% of the float of Puma Biotechnology has been sold short.Short Interest Ratio / Days to CoverPuma Biotechnology has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Puma Biotechnology has recently increased by 6.28%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPuma Biotechnology does not currently pay a dividend.Dividend GrowthPuma Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PBYI. Previous Next 3.1 News and Social Media Coverage News SentimentPuma Biotechnology has a news sentiment score of 1.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Puma Biotechnology this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for PBYI on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Puma Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Puma Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $176,342.00 in company stock.Percentage Held by Insiders21.20% of the stock of Puma Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions60.58% of the stock of Puma Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Puma Biotechnology are expected to decrease by -57.89% in the coming year, from $0.19 to $0.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Puma Biotechnology is 19.64, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 130.40.Price to Earnings Ratio vs. SectorThe P/E ratio of Puma Biotechnology is 19.64, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 113.54.Price to Earnings Growth RatioPuma Biotechnology has a PEG Ratio of 2.02. PEG Ratios above 1 indicate that a company could be overvalued. Previous Next See Top Rated MarketRank™ Stocks Here About Puma Biotechnology (NASDAQ:PBYI) StockPuma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.Read More Receive PBYI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address PBYI Stock News HeadlinesJanuary 25, 2023 | finance.yahoo.comPuma Biotechnology's (NASDAQ:PBYI) investors will be pleased with their decent 96% return over the last yearJanuary 12, 2023 | finance.yahoo.comPuma Biotechnology to Present at B. Riley Securities’ 3rd Annual Oncology ConferenceJanuary 27, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 12, 2023 | reuters.comPBYI.OQ - | Stock Price & Latest News | ReutersJanuary 9, 2023 | finance.yahoo.comPuma Biotechnology, Inc. (PBYI)December 20, 2022 | finance.yahoo.comInstitutional investors own a significant stake of 45% in Puma Biotechnology, Inc. (NASDAQ:PBYI)December 15, 2022 | finance.yahoo.comWhy Shares of Puma Biotechnology Rose This WeekDecember 1, 2022 | finance.yahoo.com15 Best Affordable Stocks Under $30January 27, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.November 22, 2022 | finance.yahoo.comIs Puma Biotechnology (PBYI) Stock a Solid Choice Right Now?November 14, 2022 | finance.yahoo.comWhy Puma Biotech (PBYI) is a Top Momentum Stock for the Long-TermNovember 11, 2022 | ca.finance.yahoo.comPBYI vs. GMAB: Which Stock Should Value Investors Buy Now?November 9, 2022 | benzinga.comShort Volatility Alert: Puma Biotechnology, Inc.November 9, 2022 | finance.yahoo.comRegeneron (REGN) Gets FDA Nod for Libtayo's Label ExpansionNovember 9, 2022 | finance.yahoo.comPuma Biotechnology Third Quarter 2022 Earnings: Beats ExpectationsNovember 8, 2022 | finance.yahoo.comWhy Puma Biotechnology, Inc. (NASDAQ:PBYI) Looks Like A Quality CompanyNovember 4, 2022 | apnews.comPuma Biotechnology Reports Third Quarter 2022 Financial ResultsNovember 4, 2022 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Puma Biotechnology (PBYI)November 4, 2022 | finance.yahoo.comAgios (AGIO) Q3 Loss Narrower Than Expected, Sales MissNovember 4, 2022 | finance.yahoo.comIntra-Cellular (ITCI) Beat on Q3 Earnings and Sales EstimatesOctober 27, 2022 | finance.yahoo.comPuma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR SymposiumSeptember 20, 2022 | finance.yahoo.comPuma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A InhibitorSeptember 11, 2022 | finance.yahoo.comPuma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022August 24, 2022 | nasdaq.comWith 53% institutional ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) is a favorite amongst the big gunsAugust 12, 2022 | finance.yahoo.comPuma Biotechnology, Inc.'s (NASDAQ:PBYI) Profit OutlookAugust 8, 2022 | finance.yahoo.comPuma Biotech (PBYI) Stock up as Q2 Earnings & Sales BeatAugust 4, 2022 | finance.yahoo.comPuma Biotechnology Reports Second Quarter 2022 Financial ResultsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PBYI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address PBYI Company Calendar Last Earnings11/03/2022Today1/27/2023Next Earnings (Estimated)3/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PBYI CUSIPN/A CIK1401667 Webwww.pumabiotechnology.com Phone(424) 248-6500Fax424-248-6501Employees196Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.00 High Stock Price Forecast$8.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+85.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.22 Trailing P/E Ratio19.64 Forward P/E Ratio22.74 P/E Growth2.02Net Income$-29,130,000.00 Net Margins4.50% Pretax Margin4.64% Return on Equity84.14% Return on Assets4.78% Debt Debt-to-Equity Ratio4.42 Current Ratio2.04 Quick Ratio1.95 Sales & Book Value Annual Sales$253.20 million Price / Sales0.78 Cash FlowN/A Price / Cash FlowN/A Book Value($0.06) per share Price / Book-72.00Miscellaneous Outstanding Shares45,640,000Free Float35,964,000Market Cap$197.16 million OptionableOptionable Beta0.92 Key ExecutivesMr. Alan H. Auerbach (Age 53)Founder, Chairman, Pres, CEO & Sec. Comp: $1.11MMr. Maximo F. Nougues (Age 54)CFO & Principal Accounting Officer Comp: $627.85kDr. Alvin F. Wong Pharm.d.Chief Scientific OfficerMr. Douglas Hunt B.Sc. (Age 58)FRAPS, Sr. VP of Regulatory Affairs, Medical Writing & Project Management Comp: $509.04kMr. Jeffrey Jerome Ludwig (Age 57)Chief Commercial Officer Comp: $735.01kMr. Mariann OhanesianSr. Director of Investor RelationsMore ExecutivesKey CompetitorsKamadaNASDAQ:KMDALifecore BiomedicalNASDAQ:LFCRAssertioNASDAQ:ASRTY-mAbs TherapeuticsNASDAQ:YMABThorne HealthTechNASDAQ:THRNView All CompetitorsInsiders & InstitutionsPatriot Financial Group Insurance Agency LLCSold 22,000 shares on 1/17/2023Ownership: 0.062%Alan H AuerbachSold 27,241 sharesTotal: $113,867.38 ($4.18/share)Maximo F NouguesSold 10,499 sharesTotal: $43,885.82 ($4.18/share)Alvin F WongSold 3,460 sharesTotal: $14,462.80 ($4.18/share)BNP Paribas Arbitrage SNCBought 6,212 shares on 11/16/2022Ownership: 0.044%View All Insider TransactionsView All Institutional Transactions PBYI Stock - Frequently Asked Questions Should I buy or sell Puma Biotechnology stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PBYI shares. View PBYI analyst ratings or view top-rated stocks. What is Puma Biotechnology's stock price forecast for 2023? 1 analysts have issued 1-year target prices for Puma Biotechnology's stock. Their PBYI share price forecasts range from $8.00 to $8.00. On average, they anticipate the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 85.2% from the stock's current price. View analysts price targets for PBYI or view top-rated stocks among Wall Street analysts. How have PBYI shares performed in 2023? Puma Biotechnology's stock was trading at $4.23 at the start of the year. Since then, PBYI shares have increased by 2.1% and is now trading at $4.32. View the best growth stocks for 2023 here. When is Puma Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023. View our PBYI earnings forecast. How were Puma Biotechnology's earnings last quarter? Puma Biotechnology, Inc. (NASDAQ:PBYI) issued its earnings results on Thursday, November, 3rd. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.10. The biopharmaceutical company earned $57.10 million during the quarter, compared to analysts' expectations of $51.40 million. Puma Biotechnology had a trailing twelve-month return on equity of 84.14% and a net margin of 4.50%. What other stocks do shareholders of Puma Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and What is Puma Biotechnology's stock symbol? Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI." Who are Puma Biotechnology's major shareholders? Puma Biotechnology's stock is owned by many different retail and institutional investors. Top institutional investors include Rice Hall James & Associates LLC (0.84%) and Patriot Financial Group Insurance Agency LLC (0.06%). Insiders that own company stock include Alan H Auerbach, Alvin F Wong, Ann Calby Miller, Douglas M Hunt, Jay M Moyes, Langley Steinert, Maximo F Nougues, Michael Patrick Miller, Richard Paul Bryce and Troy Edward Wilson. View institutional ownership trends. How do I buy shares of Puma Biotechnology? Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Puma Biotechnology's stock price today? One share of PBYI stock can currently be purchased for approximately $4.32. How much money does Puma Biotechnology make? Puma Biotechnology (NASDAQ:PBYI) has a market capitalization of $197.16 million and generates $253.20 million in revenue each year. The biopharmaceutical company earns $-29,130,000.00 in net income (profit) each year or $0.22 on an earnings per share basis. How many employees does Puma Biotechnology have? The company employs 196 workers across the globe. How can I contact Puma Biotechnology? Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The official website for the company is www.pumabiotechnology.com. The biopharmaceutical company can be reached via phone at (424) 248-6500, via email at ir@pumabiotechnology.com, or via fax at 424-248-6501. This page (NASDAQ:PBYI) was last updated on 1/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.